Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
PurposeHormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin D1 overexpression in residual tumor could re...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Breast cancer research and treatment
Year: 2017, Jahrgang: 168, Heft: 1, Pages: 179-187 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-017-4581-1 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s10549-017-4581-1 Verlag, Volltext: https://doi.org/10.1007/s10549-017-4581-1 
|
| Verfasserangaben: | S.L. Villegas, S. Darb-Esfahani, G. von Minckwitz, J. Huober, K. Weber, F. Marmé, J. Furlanetto, C. Schem, B.M. Pfitzner, B. Lederer, K. Engels, S. Kümmel, V. Müller, K. Mehta, C. Denkert, S. Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580956041 | ||
| 003 | DE-627 | ||
| 005 | 20220815010921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180913r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-017-4581-1 |2 doi | |
| 035 | |a (DE-627)1580956041 | ||
| 035 | |a (DE-576)510956041 | ||
| 035 | |a (DE-599)BSZ510956041 | ||
| 035 | |a (OCoLC)1341018460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Villegas, Sonia Lorena |e VerfasserIn |0 (DE-588)1166902331 |0 (DE-627)1030773203 |0 (DE-576)510957404 |4 aut | |
| 245 | 1 | 0 | |a Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer |c S.L. Villegas, S. Darb-Esfahani, G. von Minckwitz, J. Huober, K. Weber, F. Marmé, J. Furlanetto, C. Schem, B.M. Pfitzner, B. Lederer, K. Engels, S. Kümmel, V. Müller, K. Mehta, C. Denkert, S. Loibl |
| 264 | 1 | |c 2018 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 25 November 2017 | ||
| 500 | |a Gesehen am 13.09.2018 | ||
| 520 | |a PurposeHormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin D1 overexpression in residual tumor could recognize those patients that benefit most from such post-neoadjuvant treatment. In this study, we determined Cyclin D1 expression in residual BC after NACT. Secondary aims were to correlate Cyclin D1 expression levels with clinicopathological parameters and to assess its prognostic value after NACT.MethodsWe retrospectively assessed the nuclear expression of Cyclin D1 on tissue microarrays with residual tumor from 284 patients treated in the neoadjuvant GeparTrio (n = 186) and GeparQuattro (n = 98) trials. Evaluation was performed with a standardized immunoreactive score (IRS) after selecting a cut-off value.ResultsA high expression level (IRS ≥ 6) of Cyclin D1 was found in 37.3% of the assessed specimens. An increased Cyclin D1 expression was observed in HR-positive tumors, compared to HR-negative tumors (p = 0.02). Low Cyclin D1 levels correlated with clinical tumor stage 1-3 (p = 0.03). Among patients with HR-positive/Her2-negative tumors and high Cyclin D1 expression, a better disease-free survival (DFS) was graphically suggested, but not significant (p = 0.21).ConclusionOur study demonstrates a measurable nuclear expression of Cyclin D1 in post-neoadjuvant residual tumor tissue of HR-positive BC. Cyclin D1 expression was not prognostic for DFS after NACT. Our results and defined cut-off suggest that the marker can be used to stratify tumors according to protein expression levels. Based on this, a prospective evaluation is currently performed in the ongoing Penelope-B trial. | ||
| 534 | |c 2017 | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cyclin D-CDK4/CDK6 | |
| 650 | 4 | |a Cyclin D1 | |
| 650 | 4 | |a Cyclin D1 overexpression | |
| 650 | 4 | |a Cyclin D1 TMA | |
| 650 | 4 | |a Neoadjuvant chemotherapy | |
| 650 | 4 | |a Prognose Cyclin D1 | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 168(2018), 1, Seite 179-187 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnas |a Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer |
| 773 | 1 | 8 | |g volume:168 |g year:2018 |g number:1 |g pages:179-187 |g extent:9 |a Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10549-017-4581-1 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-017-4581-1 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180913 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 6 | ||
| 999 | |a KXP-PPN1580956041 |e 3025508795 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"role":"aut","given":"Sonia Lorena","family":"Villegas","display":"Villegas, Sonia Lorena"},{"role":"aut","given":"Frederik","family":"Marmé","display":"Marmé, Frederik"}],"id":{"eki":["1580956041"],"doi":["10.1007/s10549-017-4581-1"]},"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["S.L. Villegas, S. Darb-Esfahani, G. von Minckwitz, J. Huober, K. Weber, F. Marmé, J. Furlanetto, C. Schem, B.M. Pfitzner, B. Lederer, K. Engels, S. Kümmel, V. Müller, K. Mehta, C. Denkert, S. Loibl"]},"relHost":[{"part":{"volume":"168","extent":"9","issue":"1","text":"168(2018), 1, Seite 179-187","year":"2018","pages":"179-187"},"language":["eng"],"id":{"eki":["320433722"],"issn":["1573-7217"],"zdb":["2004077-5"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433722","disp":"Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancerBreast cancer research and treatment","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1981-","dateIssuedKey":"1981","publisher":"Springer Science + Business Media B.V. ; Kluwer"}],"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1981 -"],"title":[{"title_sort":"Breast cancer research and treatment","title":"Breast cancer research and treatment"}]}],"recId":"1580956041","type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer","title":"Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer"}],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"note":["Published online: 25 November 2017","Gesehen am 13.09.2018"]} | ||
| SRT | |a VILLEGASSOEXPRESSION2018 | ||